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BACKROUND: Testicular germ cell tumour (TGCT) is the most common cause of death from solid tumours in young men and
especially for platinum-refractory patients novel treatment approaches are urgently needed. Using an in silico screening approach for
the detection of novel cancer drugs with inhibitory effects on the tyrosine kinase activity of growth factors (e.g., VEGFR, PDGFR), we
identified two compounds (HP-2 and HP-14) with antiangiogenic and antiproliferative potency, which were evaluated in endothelial
cell models and TGCT cells.
RESULTS: HP-2 and HP-14 effectively inhibited the growth of VEGFR-2-expressing TGCT cell lines (Tera-1, Tera-2 and 2102EP) and
endothelial cell models, while they failed to supress the growth of VEGFR-2-lacking tumour cells. cDNA-microarrays revealed an
inhibition of the expression of several growth factor receptors and related signal transduction molecules. Vascular endothelial growth
factor (VEGF)-induced cell migration was also potently inhibited. Cell cycle-regulating proteins such as p21 and p27 were
upregulated, leading to an S-phase arrest. Additional in vivo evaluations confirmed the antiangiogenic potency and good tolerability of
the novel substances.
CONCLUSION: Our data show that the identified novel compounds inhibit the growth of TGCT cells and decrease angiogenic
microvessel formation. The mode of action involves cell cycle arresting effects and changes in the expression pattern of several
angiogenic genes. The novel compounds may qualify as new candidates for targeted treatment of TGCT and merit further evaluation.
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Testicular germ cell tumour (TGCT) is the most common
malignancy in the group of young men between 20 and 40 years
with increasing incidence during the last 30 years in the majority
of industrialised countries (Huyghe et al, 2003). Approximately
95% of malignant tumours of the testis are germ cell tumours (Bosl
and Motzer, 1997). Germ cell tumours are classified as semino-
matous or nonseminomatous and originate from carcinoma
in situ, also known as testicular intraepithelial neoplasia
(Looijenga and Oosterhuis, 1999). Today 490% of all patients
with metastatic germ cell cancer can be cured after receiving
standard-dose, cisplatin-based combination chemotherapy
(Kollmannsberger et al, 2006). However, a small group of patients
who relapse after cisplatin-based chemotherapy or from complete
remission have a poor prognosis (Hussain et al, 2008). Therefore,
it is very important to identify new treatment options for as much
as to develop therapies with minimal side effects to improve the
quality of life of these mostly young patients (Schrader et al, 2009).
Angiogenesis, the formation of new blood vessels, is a complex
process that includes endothelial cell proliferation, vessel sprout-
ing, vascular permeability and remodelling and maturation of
emerging vessels. This process, mainly driven by the vascular
endothelial growth factor VEGF/VEGFR-system, has a crucial role
in tumour growth, development and progression (Loges et al,
2009). The necessary requirement for the expansion and metastasis
of tumour cells is the connection to the vascular system of the
surrounding tissue. This tumour angiogenesis will supply the
tumour with sufficient oxygen and nutrients and is essential for
tumour survival (Folkman, 1971). One of the most important
signals for induction of angiogenesis is the VEGF. Vascular
endothelial growth factor represents a family of five glycoproteins
(VEGF-A–VEGF-E) in which VEGF-A (VEGF) is thought to be the
most important angiogenic factor of this family. It binds to three
structurally highly related tyrosine kinase receptors VEGFR-1
(Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 (Flt-4) with specific
functions: the binding of VEGF to VEGFR-1 leads to hematopoietic
cell development, whereas VEGFR-3 is mainly involved in
lymphatic endothelial cell development (Folkman, 1971; Ferrara
et al, 2003). VEGFR-2 regulates the vascular endothelial cell
development and is thought to be the primary receptor involved in
angiogenesis. The expression of VEGFR-2 and VEGF is directly
correlated with microvessel density and metastasis in many solid
tumours (Boocock et al, 1995; Takahashi et al, 1996; Fox et al,
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s2004; Ho ¨pfner et al, 2008). This also holds true for germ cell
tumours, in which the expression of VEGF correlates with
increased angiogenic activity, disease progression and increased
tumour microvessel density (Viglietto et al, 1996). Inhibition of the
VEGF/VEGFR system has already become a clinically relevant
strategy for innovative treatment of several urological tumours
(Krause and Van Etten, 2005; Chieffi, 2007). However, information
on the suitability for treatment of germ cell tumours remains to be
determined.
In our study, we searched for novel antiangiogenic TKIs by
using an in silico screening approach to identify yet unknown
compounds with putative antiangiogenic and antiproliferative
properties. The clinically relevant VEGFR TKI vatalanib was used
as lead structure (Wood et al, 2000). An ‘inhouse’ database with
approximately four million compounds was verified for two- and
three-dimensional similarity to vatalanib. The search revealed 15
compounds with different antiproliferative and antiangiogenic
potencies. Table 1 shows the two-dimensional similarities of
15 identified novel compounds. The purpose of this study was
to determine and analyse the antiangiogenic, antimigratory and
antiproliferative potency of the two most potent antiangiogenic
and antiproliferative compounds, named HP-2 and HP-14.
Evidence for the specific VEGFR-2 inhibition by the novel
compounds in terms of binding properties and VEGFR-2-related
inhibition of tumour cell growth was already shown in a previous
study (Schmidt et al, 2008).
MATERIALS AND METHODS
Cell lines
The human testicular carcinoma cell line Tera-1 and Tera-2 (ATCC
No. HTB-105, HTB-106) and the human renal cell carcinoma
cell line A498 (ATCC No. HTB-44) were cultured in RPMI 1640
medium (Biochrom AG, Berlin, Germany) supplemented with 10%
fetal bovine serum, 100Uml
–1 penicillin and 100mgml
–1 strepto-
mycin. The human testicular carcinoma cell line 2102EP
(Wang et al, 1981) (kindly provided by F Honecker, Hamburg,
Germany) were cultured in DMEM/Ham’s F-12 (1:1) medium
(Biochrom AG) supplemented with 10% fetal bovine serum,
100Uml
–1 penicillin and 100mgml
–1 streptomycin. The endothe-
lial cell line EA.hy926 (Edgell et al, 1983) was maintained in DMEM
(Biochrom AG) with 10% fetal bovine serum, 100Uml
–1penicillin
and 100mgml
–1 streptomycin. Human umbilical vein endothelial
cells (HUVECs) were isolated as described (Chlench et al, 2007).
Endothelial Cell Basal Medium (PromoCell, Heidelberg, Germany)
was supplemented with the SupplementPack MV (PromoCell).
HUVEC cells were used at passages 1–2. The cultures were main-
tained at 371C in a humidified atmosphere of 5% CO2. Culture
media was changed every second day and once a week the cells
were passaged using 1% Trypsin/EDTA.
Drugs
Vatalanib was obtained from LC Laboratories (Woburn, MA,
USA). HP-2 and HP-14 were purchased from Ambinter (Paris,
France). Stock solutions were prepared in DMSO, stored at  201C
and diluted to the final concentration in fresh media before each
experiment. In all experiments, the final DMSO concentration was
o0.2%.
Measurement of growth inhibition
Drug-induced changes in cell numbers were evaluated by crystal
violet staining, as described (Gillies et al, 1986). In brief, cells in
96-well plates were fixed with 1% glutaraldehyde and stained with
0.1% crystal violet. The unbound dye was removed by washing
with water. Bound crystal violet was solubilised with 0.2% Triton-
X-100. Light extinction that increases linearly with the cell number
was analysed at 570nm using an ELISA-Reader.
Western blotting
Western blotting was performed as described (Ho ¨pfner et al,
2004). In brief, whole-cell extracts were prepared by lysing
cells with RIPA buffer. Lysates containing 30mg protein was
subjected to gel electrophoresis. Proteins were transferred to PVDF
membranes by electroblotting for 1.5h. Blots were blocked in
5% skim milk powder solution (Merck, Darmstadt, Germany) for
1h, and then incubated at 41C overnight with antibodies directed
against ERK1/2 and pERK1/2 (1:500 or 1:1000, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) as well as with p21
waf1/cip1
(1:200 Cell Signaling, Danvers, MA, USA) and p27
Kip1 (1:2000 Cell
Signaling). After incubation with horseradish peroxidase-coupled
anti-IgG antibodies (1:10000, Amersham, Uppsala, Sweden) at
room temperature for at least 1h, the blot was developed using
enhanced chemiluminescent detection (Amersham) and subse-
quently exposed to Hyperfilm ECL film (Amersham) for 0.5–5min.
Reverse transcription polymerase chain reaction
(RT–PCR)
Total RNA was extracted using RNeasy Mini Kit following
the manufacturer’s instructions (Qiagen, Hilden, Germany). The
concentration and purity were measured by absorption spectro-
photometry at 260 and 280nm. The cDNA was synthesised from
2mg of total RNA using the Superscript RT kit (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s protocol.
Reverse transcription–polymerase chain reaction was carried out
in a total volume of 50ml containing 200nM of each Primer, 200mM
dNTP’s (Invitrogen), 1.5mM MgCl2 and 2U aTaq DNA-Polymerase
(Promega, Madison, WI, USA). The PCR was performed in
a Peltier thermal cycler (PTC-200, MJ-Research, Watertown, MA,
USA) with the primers and conditions indicated in Table 2 (Dias
et al, 2000; Basciani et al, 2002; Chung et al, 2005).
Migration assay
EA.hy926 endothelial cells were grown to confluence in six-well
plates. After serum starvation for 24h, the monolayer was scrat-
ched with a pipette tip along a ruler. Endothelial cell growth
medium was replenished with the new medium containing
10ngml
–1 VEGF-A (VEGF-A165 Sigma-Aldrich, Steinheim,
Germany) and 10mM of HP-2 or HP-14, respectively. Images were
taken with Kappa digital camera (Kappa opto-electronics,
Gleichen, Germany) after 24h of incubation at 371Ci na
humidified atmosphere (5% CO2). Cell migration was quantified
by using Tscratch software (Geba ¨ck et al, 2009).
DNA-microarray
Total cellular RNA was extracted from cells using ArrayGrade
Total RNA Isolation Kit (SABiosciences, Frederick, MD, USA).
RNA concentration was measured by absorption spectrophoto-
metry (GeneQuant, Biochrom, Cambridge, UK). Using the
True-Labeling AMP 2.0 amplification kit (SABiosciences), the
mRNA was reversely transcribed into cDNA and converted to
biotin-labeled cRNA using biotin-16-UTP (Roche, Mannheim,
Germany) by in vitro transcription. cRNA samples were purified
with an ArrayGrade cRNA cleanup kit (SABiosciences). Thereafter,
the probes were hybridised to the pretreated Oligo GEArray
Human Angiogenesis arrays (OHS-024, SABiosciences), which
cover 113 angiogenesis-related genes plus controls or to Human
Cancer Pathway Finder arrays (OHS-033, SABiosciences). After
several washing steps, array spots binding cRNA were detected by
chemiluminescence staining. Image acquisition was performed
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sTable 1 Characteristics and 2D structures of novel HP-compounds
2D structure Formula Molecular weight IC50 (lM)* Compound name
C20H15ClN4 346.82 410mM Vatalanib (lead structure)
C21H14Cl2N2O 381.2 NA HP-1
C21H16N2S 328.43 3.2 HP-2
C21H16N2O 312.37 7.3 HP-3
C18H14ClN3OS 355.84 NA HP-4
C21H15ClN2O 346.81 NA HP-5
C21H15ClN2O 346.816 6.4 HP-6
C21H15ClN2S 362.88 5.7 HP-7
C22H18N2S 342.46 4.1 HP-8
C21H15ClN2O 346.81 6.3 HP-10
C18H17BrN5O2 415.27 NA HP-11
C22H17N5 351.41 NA HP-12
C22H17ClN2S 376.91 NA HP-13
C20H15N3S 329.42 5.4 HP-14
C22H18N2S 342.46 NA HP-15
Abbreviation: 2D¼two-dimensional. *IC50 value determined in endothelial cells after 96 hours of incubation.
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susing X-ray films and a digital scanner. Spots were analysed and
converted to numerical data by using the GEArray Expression
Analysis Suite software (SABiosciences). Data evaluation included
background correction (substraction of minimum value) and
normalisation to reference genes. The cut off for upregulation was
set at a 1.5-fold increase in the ratio of genes in the treated
samples, whereas downregulation was determined as the 0.5-fold
expression of genes in the treated samples.
Cell cycle analysis by flow cytometry
Cell cycle analysis was performed by a modified method of Fried
et al (1976). Cells were seeded at a concentration of 10
5cellsml
–1
and treated with 10mM HP-14 for 24h. Cells were then washed
with PBS and fixed in PBS/formaldehyde 2% (vol/vol) on ice for
30min. Afterwards cells were incubated in ice cold ethanol/PBS
(2:1 vol/vol) overnight at  201C and pelleted. Resuspension in
PBS containing 40mgml
–1RNase A followed. After incubation for
30min at 371C, cells were pelleted again and resuspended in PBS
containing 50mgml
–1 propidium iodide. Cells were then analysed
on a FACSCalibur flow cytometer using CellQuestPro Software (BD
Biosciences, Heidelberg, Germany) and FlowJo Software (Tree star,
Ashland, OR, USA).
Chick chorioallantoic membrane (CAM)
angiogenesis assay
Fertilised chicken eggs (Lohmann Tierzucht, Cuxhaven, Germany)
were bred in an incubator at 371C in constant humidity for 3 days.
After day 3, a square window was cut into the shell of each egg, and
5ml of albumen was removed to allow detachment of the developing
chorioallantoic membrane from the shell. The window was sealed
with tape, and the eggs were bred in the incubator for additional
7 days. On day 11, the tapes were removed and the CAMs were
treated with the different compounds as described (Ribatti et al,
1997). In brief, a small ring was placed onto the CAM and either
100mlo fP B S( n e g a t i v ec o n t r o l )o r1 0 0 ml of PBS containing HP-2
and HP-14 were added. After 48h of incubation, the CAMs were
examined and in vivo pictures were taken using a stereomicroscope
equipped with a Kappa digital camera system. For more detailed
investigations the CAMs were fixed with 4% paraformaldehyde,
dissected and transferred to glass slides and analysed under the
microscope (Zeiss Axioplan, Carl Zeiss, Oberkochen, Germany)
equipped with a MBF Bioscience camera system (MBF Bioscience,
Williston, VT, USA). The response to drug treatment was assessed
by examining the alterations of the CAM differing from the controls.
RESULTS
VEGFR expression
The expression of VEGFR-1 and VEGFR-2 was examined in
endothelial cells (HUVEC and EA.hy926) and in the urologic
tumour cell lines Tera-1, Tera-2, 2102EP and A498. Reverse
transcription–PCR revealed a robust expression of VEGFR-2 in
TCGT cells (Tera-1, Tera-2 and 2102EP) and in the two endothelial
cell models. However, in the additionally tested renal cell
carcinoma cells (A498) no appreciable expression of VEGFR-2
was detected. No expression of VEGFR-1 was detected in A498 and
Tera-1 cells (Figure 1).
Growth inhibitory effects
To determine the growth inhibitory effects of HP-2 and HP-14 on
tumour and endothelial cells, crystal violet staining was performed
after 48h of continuous incubation with rising concentrations
of either compound. Both, HP-2 as well as HP-14 led to time- and
dose-dependent growth inhibition of HUVEC, EA.hy926 and TGCT
cells (Tera-1, Tera-2 and 2102EP) of up to 480%. Interestingly,
VEGFR-lacking A498 cells did not respond to HP-treatment
(Figure 2). Compared with the growth inhibitory effects of the
lead structure vatalanib, the antiproliferative effects of our
novel compounds were much more pronounced, especially in the
TGCT cells.
Unspecific cytotoxicity of HP-2 and HP-14 was excluded by
measurement of LDH-release into the supernatant of treated cells.
Neither endothelial cells nor TGCT cells showed an increase
in LDH release 41% as compared with untreated control cells,
revealing that unspecific cytotoxicity does not account for the
observed antiproliferative effects of the two compounds (data not
shown).
Gene expression profiling
To shed light on the pathways modulated by the novel compounds
two different cDNA-microarrays were performed. The human
VEGFR-1
VEGFR-2
GAPDH
A498
Tera-1
Tera-2
2102 EP
HUVEC
EA.hy 926
Figure 1 Expression of VEGFR-1 and VEGFR-2 in endothelial and
urologic tumour cells. The TGCT cell lines Tera-1, Tera-2 and 2102EP
show a strong expression of VEGFR-2 and a weak expression of VEGFR-1.
By contrast urologic A498 tumour cells did not express any of the two
receptors. Both endothelial cell models (EA.hy926 and HUVEC) showed
the expected robust expression of VEGFR-1 and -2.
Table 2 RT–PCR primer used for the detection of VEGF receptors
Genes Primers (50-30)
Gene bank
accession
number
Product
size (bp)
Denaturing
temperature
and time (s)
Annealing
temperature
and time (s)
Extension
temperature
and time(s)
Number
of cycles
VEGFR-1 F:ATTTGTGATTTTGGCCTTGC NM_002019 550 941C (60) 651C (45) 721C (120) 35
R:CAGGCTCATGAACTTGAAAGC
VEGFR-2 F:GTGACCAACATGGAGTCGTG NM_002253 660 941C (60) 651C (45) 721C (120) 35
R:CCAGAGATTCCATGCCACTT
GAPDH F:CCTGACCTGCCGTCTAGAAA NM_002046 276 941C (15) 551C (30) 681C (60) 35
R:TACTCCTTGGAGGCCATGTG
Abbreviations: RT–PCR¼reverse transcription polymerase chain reaction; VEGF¼vascular endothelial growth factor.
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sangiogenesis array was performed with endothelial cells (HUVEC)
and TGCT cells (Tera-1) to profile the expression of 113 genes
involved in angiogenesis after treatment with HP-14 (15mM for
48h). The human cancer pathway finder array was used to
determine the expression pattern of genes involved in cancer
relevant pathways such as transformation and tumourigenesis of
TGCT cells (Tera-1). On HP-14 treatment up- or downregulation of
35 genes involved in angiogenesis were detected in HUVEC cells
(Table 3). The angiogenesis-promoting genes Tie-2 and IL8
showed a strong downregulation, while the antiangiogenic
regulator endostatin was markedly upregulated.
In Tera-1 cells, HP-14 induced the modulation of 40 genes
responsible for cellular functions such as growth, signal transduc-
tion, cell cycle regulation and angiogenesis (Table 4). Genes
*IC50 value determined after 48 hours 
HUVEC
Vatalanib
HP-2
HP-14 4.8 M* 3.6 M 5.6 M >10 M 3.3 M 6.2 M*
8.9 M 8.7 M 10 M* >10 M 3.5 M 3.2 M
>10 M >10 M >10 M* >10 M >10 M >10 M
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Figure 2 Antiproliferative effects of HP-2, HP-14 and vatalanib measured after 48 or 96h. IC50 values of HP-2, HP-14 and vatalanib were determined in
EA.hy926 (A), HUVEC (B), A498 (C), 2102EP (D), Tera-1 (E) and Tera-2 (F) cells. HP-2 and HP-14 exerted marked growth inhibitory effects in VEGFR-
expressing TGCT cells Tera-1, Tera-2, 2102EP and in endothelial cell models in a time- and dose-dependent manner. No appreciable growth inhibition was
observed in VEGFR-2-lacking A498 cells. Data are given as percentage of control, value mean; bars, s.e. (n¼4).
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sencoding proteins regulating the progression of the cell cycle
(CDK2, CDC25A) were strong suppressed and the major cell cycle
inhibitor CDKN1A was elevated. In addition, a suppression of the
proangiogenic growth factors PDGFA, PDGFB and HTATIP2 was
detected, as well as an elevation of the angiogenic inhibitor
endostatin.
Both, in endothelial as well as in TGCT cells HP-14 induced a
marked downregulation of VEGFR-2 (KDR/Flk-1). Moreover, in
Tera-1 cells the VEGFR-2 downstream signalling transduction
molecule AKT1 was suppressed, suggesting a functional role of
HP-14 in these processes.
The Tables 3 and 4 summarise the findings on up- and
downregulation of angiogensis- and cancer pathway-specific genes
of endothelial and TGCT cells, respectively.
MAPK-inhibition by novel compounds
Inhibition of ERK1/2 phosphorylation was examined in EA.hy926
cells. Cells were incubated with 0, 5 and 10mM of HP-2 or HP-14 for
24h. Both compounds inhibited the phosphorylation of ERK1/2
(Figure 3), whereas the total amount of ERK protein remained
unaffected. Maximal effects were observed with 10mM of HP-14.
At equimolar concentration HP-2 and HP-14 show stronger
inhibition of ERK1/2 phosphorylation as compared with vatalanib.
Comparable results were obtained in the TGCT cell lines (data not
shown).
Drug-induced cell cycle arrest
Expression of the two major cell cycle regulators, the cyclin-
dependent kinase inhibitors p21
waf/cip1 and p27
Kip1, were examined
by western blotting. Incubation of Tera-1 and EA.hy 926 cells
with HP-2, HP-14 or vatalanib for 24h resulted in an increase in
p21
waf/cip1 and p27
Kip1 expression, suggesting that the mode of
action of the HP-substances involves cell cycle arresting effects
(Figures 4A and B). To confirm these findings flow cytometric cell
cycle analyses was performed on Tera-1 cells. In this study, HP-14
treatment led to an arrest of cells in the S-phase of the cell cycle,
accompanied by a respective decrease in the proportion of cells in
the G2-phase, whereas no significant increase in apoptotic cells in
the SubG1 population was detected (Figure 4C).
Effects on cell migration
Cell migration is necessary for endothelial angiogenesis as well
as for cancer cell invasion and metastasis. Performing scratch
wound assays we determined the antimigratory effects of HP-2 and
HP-14 on endothelial cell migration. EA.hy926 cell monolayers
were serum starved for 24h. Thereafter the monolayers were
scratched with a pipette tip and scratch closure was stimulated
by VEGF (10ngml
–1). HP-2 and HP-14 pretreated cells showed a
decreased migration as compared with VEGF-stimulated control
cells. The migratory inhibition of HP-compounds amounted to
Table 3 Genes regulated in HUVEC cells in response to HP-14 15mM for 48h predicted by human angiogenesis array
Symbol Fold Product
Downregulated genes
ANPEP 0.48 Alanyl aminopeptidase
EPAS1 0.48 Endothelial PAS domain protein 1
EGF 0.46 Epidermal growth factor
EFNA2 0.45 Ephrin-A2
KDR 0.44 Kinase insert domain receptor (VEGFR-2)
NRP1 0.37 Neuropilin 1
PLAU 0.32 Plasminogen activator, urokinase
TEK 0.25 TEK tyrosine kinase, endothelial
CCL11 0.23 Chemokine ligand 11
IL8 0.21 Interleukin 8
ECGF1 0.19 Endothelial cell growth factor 1 (platelet-derived)
TNNT1 0.17 Troponin T type 1
TIMP3 0.12 TIMP metallopeptidase inhibitor 3
NOTCH4 0.11 Notch homolog 4
EFNA1 0.10 Ephrin-A1
TNFRSF12A 0.09 Tumor necrosis factor receptor superfamily, member 12A
TIMP2 0.08 TIMP metallopeptidase inhibitor 2
TGFA 0.07 Transforming growth factor, a
VEGFA 0.06 Vascular endothelial growth factor A
EFNA3 0.04 Ephrin-A3
PGF 0.04 Placental growth factor, vascular endothelial growth factor-related protein
AKT1 0.04 V-akt murine thymoma viral oncogene homolog 1
PDGFB 0.03 Platelet-derived growth factor b polypeptide
IL1B 0.01 Interleukin 1, b
Upregulated genes
ANPEP 1.64 Alanyl aminopeptidase
COL18A1 1.96 Collagen, type XVIII, a 1
IL6 2.19 Interleukin 6
EDG1 2.23 Endothelial differentiation, sphingolipid G-protein-coupled receptor, 1
VEGFB 2.29 Vascular endothelial growth factor B
TIE1 2.37 Tyrosine kinase with immunoglobulin-like and EGF-like domains 1
MMP2 2.41 Matrix metallopeptidase 2
TIMP1 2.45 TIMP metallopeptidase inhibitor 1
ENG 2.56 Endoglin
CXCL1 2.78 Chemokine ligand 1
EFNB2 2.93 Ephrin-B2
Abbreviation: HUVEC¼human umbilical vein endothelial cell.
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sa maximum of 38% after 24h, as determined by TSCRATCH
(Figure 5).
In vivo evaluation of HP-2- and HP-14-induced inhibition
of angiogenesis
Antiangiogenic effects of HP-2 and HP-14 on microvessel
formation of the developing CAM was assessed after 48h of
incubation. The capillary plexus and the immature larger
supplying vessels (arteries and veins) were visible at the beginning
of the experiment (Figures 6A–C). After 2 days, the PBS-treated
control CAM (Figure 6D) showed mature large vessels (arrow) and
a pronounced capillary plexus. By contrast, treatment with HP-2
(10mM) led to huge non-perfused areas of the CAM. Especially the
smaller supplying vessels were influenced by HP-2 treatment
(Figure 6E), whereas no obvious influence was observed on the
capillary plexus (star). HP-14 had the strongest effect on the CAM
vasculature. HP-14 (10mM, 48h) led to an increase in non-perfused
areas and to an obvious degeneration of the vasculature and the
capillary plexus (Figures 6F and I).
Table 4 Genes regulated in Tera-1 cells in response to HP-14 15mM for 48h predicted by human angiogenesis and human cancer pathway array
Symbol Fold Product
Downregulated genes
PDGFA 0.51 Platelet-derived growth factor a polypeptide
NFKB1 0.29 Nuclear factor of kappa light polypeptide gene enhancer in B cells 1
NFKBIA 0.23 Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor
PDGFB 0.22 Platelet-derived growth factor b polypeptide
MTA1 0.22 Metastasis-associated 1
KDR 0.15 Kinase insert domain receptor (a type III receptor tyrosine kinase)
CXCL5 0.14 Chemokine (C-X-C motif) ligand 5
CDKN1B 0.14 Cyclin-dependent kinase inhibitor 1B (p27, Kip1)
MMP2 0.14 Matrix metallopeptidase 2
MTA2 0.13 Metastasis-associated 1 family
JUN 0.12 Jun oncogene
CDK2 0.07 Cyclin-dependent kinase 2
SERPINB5 0.07 Serpin peptidase inhibitor
ITGA4 0.06 Integrin, a 4
BRCA2 0.05 Breast cancer 2
EGFR 0.05 Epidermal growth factor receptor
AKT1 0.04 V-akt murine thymoma viral oncogene homolog 1
PRKDC 0.04 Protein kinase
HTATIP2 0.04 HIV-1 Tat interactive protein
FGF2 0.04 Fibroblast growth factor 2
CDC25A 0.03 Cell division cycle 25 homolog A
SERPINB2 0.03 Serpin peptidase inhibitor
Upregulated genes
FGFR2 1.51 Fibroblast growth factor receptor 2
COL18A1 1.59 Collagen, type XVIII, 1
CCNE1 1.60 Cyclin E1
PNN 1.64 Pinin, desmosome-associated protein
TIE1 1.74 Tyrosine kinase with immunoglobulin-like and EGF-like domains 1
ITGB5 1.93 Integrin, b 5
CDK4 2.03 Cyclin-dependent kinase 4
NME1 2.03 Non-metastatic cells 1, protein (NM23A)
ITGB1 2.07 Integrin, b 1
BIRC5 2.11 Baculoviral IAP repeat-containing 5 (survivin)
TIMP1 2.11 TIMP metallopeptidase inhibitor 1
VEGFB 2.21 Vascular endothelial growth factor B
TNFRSF1A 2.23 Tumor necrosis factor receptor superfamily, member 1A
TNFRSF10B 2.24 Tumor necrosis factor receptor superfamily, member 10b
CDKN1A 2.27 Cyclin-dependent kinase inhibitor 1A (p21, Cip1)
PLAU 2.93 Plasminogen activator, urokinase
ITGA3 12.93 Integrin, a 3
TERT 24.59 Telomerase reverse transcriptase
0
Vatalanib (M) HP-2 (M) HP-14 (M)
-Actin
ERK
p-ERK
5 10 0 5 10 0 5 10
Figure 3 Treatment of EA.hy926 cells with HP-2 and HP-14 led to a dose-dependent decrease in ERK1/2 phosphorylation, whereas the expression of
total ERK1/2 protein was not affected. Compared with vatalanib the inhibitory effect of HP-2 and HP-14 was more pronounced.
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sDISCUSSION
Regardless of the generally successful platinum-based treatment
possibilities for patients with metastatic testicular germ cell cancer,
there are still subgroups of patients whose prognosis is poor. For
instance, in patients with strongly reduced initial creatinine
clearance adequate high-dose chemotherapy is problematic or
even impossible because of the increasing risk of a further loss of
renal function. Another problem is the poor response of recurrent
tumours to second-line therapy and the dose limitation, leading to
discontinuation of second salvage treatment with high-dose
polychemotherapy before achieving the eradication of the
advanced tumours. So in case of patients with primary platinum-
resistant and/or recurrent tumours or those that are unable to
undergo systemic cisplatin-based chemotherapy, alternative treat-
ment are urgently needed (Lorch et al, 2007; Schrader et al, 2009).
Searching for novel non-platinum-based treatment approaches,
we analysed and characterised the antiangiogenic and antiproli-
ferative effects of two novel small molecule inhibitors, HP-2 and
HP-14. The compounds were derived from in silico screenings
using the clinically relevant VEGFR tyrosine kinase inhibitor
vatalanib as the lead structure.
The rationale for choosing a VEGFR tyrosine kinase inhibitor as
a lead structure was deduced from findings that proangiogenic
VEGF is often increased in patients with TGCTs and increases
metastatic potential of TGCTs (Fukuda et al, 1999; Aigner et al,
2003; Bentas et al, 2003). Moreover, the expression of VEGFR-2,
which is the most important angiogenic growth factor receptor,
has been implicated in the pathogenesis of testicular germ cell
(Jones et al, 2000; Devouassoux-Shisheboran et al, 2003).
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Figure 4 Expression of the cyclin-dependent kinase inhibitors (p21
waf/Cip1, p27
Kip1) was examined by western blotting. Incubation of Tera-1 (A) and
EA.hy926 (B) with HP-2, HP-14 and vatalanib resulted in an increase in the expression of the cell cycle inhibitors p21
waf/Cip1 and p27
Kip. FACS analysis of
HP-14 (10mM) treated Tera-1 cells revealed an arrest in the S-phase of the cell cycle, with a concomitant decrease in cells in the G2/M phase and no
significant increase in apoptotic cells in the SubG1 population (C).
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Figure 5 Antimigratory effects of HP-2 and HP-14 were analysed by
performing scratch wound assays. Serum-starved cell monolayers were
scratched with a pipette tip and migration was stimulated by application of
VEGFA (10ngml
–1). Compared with control the migration of HP-treated
cells was reduced by B40%. Data are given as percentage of control
(means±s.e.m. of three independents experiments).
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clinically relevant strategy for treatment of some urological
cancers, especially those refractory to the standard chemotherapy
(Voigt et al, 2006; Fenner et al, 2008; Castillo-A ´vila et al, 2009),
whereas TGCTs are not systematically analysed in this respect.
In a recent phase II study, the multikinase inhibitor sunitinib
blocking the tyrosine kinase activity of PDGFR, VEGFRs, c-kit and
RET showed good tolerability in patients with multiply relapsed or
refractory GCT. However, the clinical outcome was rather poor.
Nevertheless, the observed decline of angiogenic tumour markers
during the treatment suggested that pathways inhibited by
sunitinib, such as the VEGF-pathway may be of particular
importance for GCT biology. As these angiogenic pathways were
presumably not enough suppressed by sunitinib – at least at the
doses used in this trial (Feldman et al, 2009), we searched for a
more potent and specific VEGFR-inhibitor, which may show a
more pronounced antiangiogenic effect in GCT.
In our study, we could show that the two novel compounds,
HP-2 and HP-14, strongly inhibit the proliferation of VEGFR-
positive TGCT cells in a dose-dependent manner. Both agents
also inhibited the proliferation of endothelial cells with IC50 values
that were below those of vatalanib. VEGFR specificity of the
compounds was shown in experiments with VEGFR-negative renal
cell carcinoma cells, which did not respond to treatment with
either vatalanib or HP-compounds.
To examine the underlying molecular events of the novel
compounds, we profiled transcriptional changes in both TGCT
cells as well as in endothelial cells by cDNA microarrays. HP-14
regulated a variety of genes, most of which could be ascribed to
cellular functions such as growth, signal transduction and
regulation of the cell cycle. On HP-treatment a significant
reduction in VEGFR-2 expression was observed in both Tera-1
and HUVEC cells. In addition, the expression of AKT-1 (protein
kinase B), a downstream signal transduction molecule of VEGFR-2
was also detected (Takano et al, 2008). Earlier findings by
Anderson et al showed the cell proliferative effects of AKT-1,
which can be activated by VEGFR-2 through protein kinase-C-
dependent signalling (Anderson et al, 2008). Furthermore, HP-14
treatment also inhibited the expression of other angiogenic growth
factors such as PDGFA, PDGFB or FGF-2, each of them being
implicated in the promotion of testicular germ cell cancer
(Peltoma ¨ki et al, 1991; Bentas et al, 2003). Another angiogenic
factor that was suppressed by HP-14, was the HIV-1 Tat interactive
protein (HTATIP2). This proangiogenic growth factor binds and
activates VEGFR-2, thereby mediating cell proliferation, cell
migration and cell survival (Albini et al, 1996). These data show
that angiogenesis reflected by the serum concentrations of growth
factors have a functional role in tumour growth of testicular germ
cell cancer and that inhibition of these factors may thus be a
promising treatment option.
HP-14 also increased the expression of antiangiogenic genes
such as the angiogenesis inhibitor endostatin (COL18A1). Endo-
statin is a protein that is supposed to neutralise many VEGF-A-
induced effects such as VEGF-induced endothelial cell migration,
neovascularisation and vascular permeability (Yamaguchi et al,
1999; Takahashi et al, 2003). Thus, the upregulation of endostatin
in endothelial cells during HP-14 treatment could be an explana-
tion of antiangiogenic potency of this novel compound.
The antiproliferative mode of action of the novel compounds
also involved cell cycle-regulating effects in TGCT cells. Defective
function of cell cycle regulators is a main cause for tumour
development and progression. For example, the cell cycle
promoter cyclin D2 is frequently overexpressed in TGCTs, while
cell cycle inhibitors, such as p21 are frequently suppressed
(Chaganti and Houldsworth, 2000). Successful therapeutic strate-
gies will thus have to balance or bypass this impaired signalling.
In our study, we could show that treatment of TGCT cells with
HP-compounds raised the expression of the cell cycle-inhibiting
48 h
0 h
a
v
v
v
a
a
v
a
v
a
v
HP-14 10 M HP-2 10 M Control (PBS)
ABC
DEF
GHI
Figure 6 HP-2- and HP-14-induced vasodegeneration of the developing CAM of fertilised chicken eggs. Upper panel (A–C) depicts CAMs before
treatment. In the middle panel, effects of 48h of treatment with PBS (control) (D), HP-2 (10mM)( E) or HP-14 (10mM)( F) are shown. (a¼artery and
v¼vein). The lower panel (G–I) shows microscopic pictures taken from dissected CAMs after treatment. In untreated and control CAM’s (A–D), the
vascular network consisted of a continuously perfused capillary plexus (star) and larger vessels (arrow). HP-2 and HP-14 induces a degeneration of the
vascular network, which was identified as unperfused areas and changes in the small supplying vessels.
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Our observation that HP-treatment-induced S-phase arrest and
p21 overexpression is in agreement with a previous report that
transduction of the p21 gene resulted in an S-phase arrest
(Ogryzko et al, 1997; Radhakrishnan et al, 2004; Zhu et al,
2004). Surprisingly, we also observed an increase in p27 expression
on HP-treatment. In general, p27 is associated with an arrest in the
G1-phase of the cell cycle. Nevertheless, p27 has also been shown
to induce S-phase arrest of human hepatocellular carcinoma cells
(Fuke et al, 2007). So far, the exact mechanism underlying
p27-induced S-phase arrest remains to be examined. However,
Sa and Stacey recently showed that growth signalling pathways,
such as the AKT-pathway can regulate p27 expression in a cell
cycle phase-independent manner. AKT inhibition led to an
increase in p27 expression of cells that were arrested in the
S-phase (Sa and Stacey, 2004). In our gene array experiments,
we also observed an inhibition of the AKT because of HP-14
treatment. Thus, it is at least feasible that the S-phase arrest of
HP-treated TGCT cells is mainly induced by an increase in p21,
whereas the concomitantly observed AKT inhibition might lead
to increasing levels of p27 of S-phase arrested cells. However,
further investigations will have to clarify the exact role of p27
during HP-induced cell cycle arrest of TGCT cells.
The p21 expression is also correlated with a reduction of the cell
cycle-controlling phosphatase protein cdc25A (de Oliveira et al,
2009), a protein that was found to be downregulated by the
novel HP-compounds in TGCT cells. Suppression of cdc25A is
implicated in the inhibition of tumour growth-promoting MAPK
activity (Wang et al, 2008). The MAPK pathway protein ERK1/2
(extracellular signal-regulated kinase 1/2) is activated by VEGFR-2
(Rubinfeld and Seger, 2005; Narasimhan et al, 2009). Correspond-
ing to the postulated VEGFR-specific action of the HP-compounds,
we could show a decrease in ERK1/2 activity after HP-treatment.
Endothelial cell migration is one of the key characteristics in
VEGFR-2-mediated angiogenesis (Shibuya, 2006). In this study, we
could show that HP-2 and HP-14 both inhibited endothelial cell
migration and suppress in vivo neovascularisation in a chorio-
allantoic membrane assay. Further evaluations will have to clarify
the compatibility of the novel HP-compounds in vivo. In this
respect, it is noteworthy that preliminary studies on healthy mice
showed promising tolerability of the HP-substances (50mgkg
–1)
when given in 48h intervals for seven days. Treated mice (n¼7)
did neither show weight loss or any altered behaviour. Histological
examination of kidney, spleen, lung and liver of the dispatched
animals did not show abnormalities or signs of inflammatory
infiltrations (data not shown).
In summary, our study showed that the identified novel
compounds are able to potently block TGCT cell growth and
angiogenesis in vitro and in vivo. The inhibitory effects of the
novel compounds were even more pronounced than those of the
clinically relevant VEGFR tyrosine kinase inhibitor, vatalanib,
which was used as the lead structure for the identification of
structurally related novel compounds with antiangiogenic and
antiproliferative potency. The complex mode of action of
HP-compounds involved cell cycle-arresting effects as well as a
shifting of the balance of pro- and antiangiogenic genes towards
angiogenic suppression and antiangiogenic stimulation (Baeriswyl
and Christofori, 2009). The fact that only the growth of VEGFR-2-
expressing endothelial and TGCT cells was markedly inhibited,
suggests that VEGFR-2 is the major target of the novel
HP-compounds. On the basis of our findings, we think that the
presented compounds may become promising candidates for
innovative approaches in TGCT treatment and warrant further
evaluation.
ACKNOWLEDGEMENTS
We are indebted to Dr K Kapp from the Institute of Molecular
Biology and Bioinformatics, Free University Berlin for her
excellent support in FACS analysis. We thank Gaby Beyer for
preparing the human umbilical cord samples. Bianca Nitzsche was
funded by Urologic Research Foundation Berlin. Bjo ¨rn Hoffmann
was supported by a grant (‘Therapeutic Systems Immunology’) of
the Bundesministerium fu ¨r Forschung und Technik (BMBF).
REFERENCES
Aigner A, Brachmann P, Beyer J, Jager R, Raulais D, Vigny M, Neubauer A,
Heidenreich A, Weinknecht S, Czubayko F, Zugmaier G (2003) Marked
increase of the growth factors pleiotrophin and fibroblast growth factor-2
in serum of testicular cancer patients. Ann Oncol 14: 1525–1529
Albini A, Soldi R, Giunciuclio D, Girauo E, Benelli R, Primo L, Noonan D,
Salio M, Camussi G, Rock W, Bussolino F (1996) The angiogenesis
induced by HIV-1 Tat protein is mediated by the Flk-1/KDR receptor on
vascular endothelial cells. Nat Med 2: 1371–1375
Anderson JC, McFarland BC, Gladson CL (2008) New molecular targets
in the angiogenic vessels of glioblastoma tumors. Expert Rev Mol Medi
10: e23
Baeriswyl V, Christofori G (2009) The angiogenic switch in carcinogenesis.
Semin Cancer Biol 19: 329–337
Basciani S, Mariani S, Arizzi M, Ulisse S, Rucci N, Jannini EA, Rocca CD,
Manicone A, Carani C, Spera G, Gnessi L (2002) Expression of platelet-
derived growth factor-A (PDGF-A), PDGF-B, and PDGF receptor-{alpha}
and -{beta} during human testicular development and disease. J Clin
Endocrinol Metab 87: 2310–2319
Bentas W, Beecken W, Glienke W, Binder J, Schuldes H (2003) Serum levels
of basic fibroblast growth factor reflect disseminated disease in patients
with testicular germ cell tumors. Urol Res 30: 390–393
Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ,
Wright KA, Twentyman PR, Smith SK (1995) Expression of vascular
endothelial growth factor and its receptors flt and KDR in ovarian
carcinoma. J Natl Cancer Inst 87: 506–516
Bosl GJ, Motzer RJ (1997) Testicular germ-cell cancer. N Engl J Med 337:
242–254
Castillo-A ´vila W, Piulats JM, Garcia del Muro X, Vidal A, Condom E,
Casanovas O, Mora J, Germa ` JR, Capella ` G, Villanueva A, Vin ˜als F (2009)
Sunitinib inhibits tumor growth and synergizes with cisplatin in
orthotopic models of cisplatin-sensitive and cisplatin-resistant human
testicular germ cell tumors. Clin Cancer Res 15: 3384–3395
Chaganti RSK, Houldsworth J (2000) Genetics and biology of adult human
male germ cell tumors. Cancer Res 60: 1475–1482
Chieffi P (2007) Molecular targets for the treatment of testicular germ cell
tumors. Mini Rev Med Chem 7: 755–759
Chlench S, Mecha Disassa N, Hohberg M, Hoffmann C, Pohlkamp T,
Beyer G, Bongrazio M, Da Silva-Azevedo L, Baum O, Pries AR,
Zakrzewicz A (2007) Regulation of Foxo-1 and the angiopoietin-2/Tie2
system by shear stress. FEBS Lett 581: 673–680
Chung C, Yeh K, Hsu NC, Chang JH, Lin J, Horng H, Chang C (2005)
Expression of c-kit protooncogene in human hepatocellular carcinoma.
Cancer Lett 217: 231–236
de Oliveira PEQ, Zhang L, Wang Z, Lazo JS (2009) Hypoxia-mediated
regulation of Cdc25A phosphatase by p21 and miR-21. Cell Cycle
(Georgetown, TX) 8: 3157–3164
Devouassoux-Shisheboran M, Mauduit C, Tabone E, Droz JP, Benahmed M
(2003) Growth regulatory factors and signalling proteins in testicular
germ cell tumours. APMIS: Acta Pathologica, Microbiologica,
Et Immunologica Scandinavica 111: 212–224; discussion 224
Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A,
Hyjek E, Gill M, Hicklin DJ, Witte L, Moore MA, Rafii S (2000) Autocrine
stimulation of VEGFR-2 activates human leukemic cell growth and
migration. J Clin Invest 106: 511–521
Molecular therapy of testicular germ cell tumours
B Nitzsche et al
27
British Journal of Cancer (2010) 103(1), 18–28 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sEdgell CJ, McDonald CC, Graham JB (1983) Permanent cell line expressing
human factor VIII-related antigen established by hybridization.
Proc Natl Acad Sci USA 80: 3734–3737
Feldman DR, Turkula S, Ginsberg MS, Ishill N, Patil S, Carousso M, Bosl GJ,
Motzer RJ (2009) Phase II trial of sunitinib in patients with relapsed or
refractory germ cell tumors. Invest New Drugs 28: 523–528
Fenner MH, Beutel G, Gru ¨nwald V (2008) Targeted therapies for patients
with germ cell tumors. Expert Opinion Invest Drugs 17: 511–522
Ferrara N, Gerber H, LeCouter J (2003) The biology of VEGF and its
receptors. Nat Med 9: 669–676
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J
Med 285: 1182–1186
Fox SB, Turley H, Cheale M, Bla ´zquez C, Roberts H, James N, Cook N,
Harris A, Gatter K (2004) Phosphorylated KDR is expressed in the
neoplastic and stromal elements of human renal tumours and shuttles
from cell membrane to nucleus. J Pathol 202: 313–320
Fried J, Perez A, Clarkson B (1976) Flow cytofluorometric analysis of cell
cycle distributions using propidium iodide. Properties of the method and
mathematical analysis of the data. J Cell Biol 71: 172–181
Fuke H, Shiraki K, Sugimoto K, Tanaka J, Beppu T, Yoneda K,
Yamamoto N, Ito K, Masuya M, Takei Y (2007) Jak inhibitor induces S
phase cell-cycle arrest and augments TRAIL-induced apoptosis in human
hepatocellular carcinoma cells. Biochem Biophys Res Commun 363:
738–744
Fukuda S, Shirahama T, Imazono Y, Tsushima T, Ohmori H, Kayajima T,
Take S, Nishiyama K, Yonezawa S, Akiba S, Akiyama S, Ohi Y (1999)
Expression of vascular endothelial growth factor in patients with
testicular germ cell tumors as an indicator of metastatic disease. Cancer
85: 1323–1330
Geba ¨ck T, Schulz MMP, Koumoutsakos P, Detmar M (2009) TScratch:
a novel and simple software tool for automated analysis of monolayer
wound healing assays. BioTechniques 46: 265–274
Gillies RJ, Didier N, Denton M (1986) Determination of cell number in
monolayer cultures. Anal Biochem 159: 109–113
Ho ¨pfner M, Schuppan D, Scheru ¨bl H (2008) Growth factor receptors and
related signalling pathways as targets for novel treatment strategies of
hepatocellular cancer. World J Gastroenterol: WJG 14: 1–14
Ho ¨pfner M, Sutter AP, Huether A, Schuppan D, Zeitz M, Scheru ¨bl H (2004)
Targeting the epidermal growth factor receptor by gefitinib for treatment
of hepatocellular carcinoma. J Hepatol 41: 1008–1016
Hussain SA, Ma YT, Palmer DH, Hutton P, Cullen MH (2008) Biology of
testicular germ cell tumors. Expert Rev Anticancer Ther 8: 1659–1673
Huyghe E, Matsuda T, Thonneau P (2003) Increasing incidence of testicular
cancer worldwide: a review. J Urol 170: 5–11
Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D, Turley H, Valtola R,
Bicknell R, Harris AL (2000) Angiogenesis and lymphangiogenesis in
stage 1 germ cell tumours of the testis. BJU Int 86: 80–86
Kollmannsberger C, Nichols C, Bokemeyer C (2006) Recent advances in
management of patients with platinum-refractory testicular germ cell
tumors. Cancer 106: 1217–1226
Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer
therapy. N Engl J Med 353: 172–187
Loges S, Mazzone M, Hohensinner P, Carmeliet P (2009) Silencing or
fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
Cancer Cell 15: 167–170
Looijenga LH, Oosterhuis JW (1999) Pathogenesis of testicular germ cell
tumours. Rev Reprod 4: 90–100
Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IGH,
Berdel WE, Weissinger F, Schleicher J, Egerer G, Haas A, Schirren R,
Beyer J, Bokemeyer C, Rick O (2007) Single versus sequential high-dose
chemotherapy in patients with relapsed or refractory germ cell tumors: a
prospective randomized multicenter trial of the German Testicular
Cancer Study Group. J Clin Oncol Off J Am Soc Clin Oncol 25: 2778–2784
Narasimhan P, Liu J, Song YS, Massengale JL, Chan PH (2009) VEGF
stimulates the ERK 1/2 signaling pathway and apoptosis in cerebral
endothelial cells after ischemic conditions. Stroke 40: 1467–1473
Ogryzko VV, Wong P, Howard BH (1997) WAF1 retards S-phase
progression primarily by inhibition of cyclin-dependent kinases.
Mol Cell Biol 17: 4877–4882
Peltoma ¨ki P, Alfthan O, de la Chapelle A (1991) Oncogenes in human
testicular cancer: DNA and RNA studies. Br J Cancer 63: 851–858
Radhakrishnan SK, Feliciano CS, Najmabadi F, Haegebarth A, Kandel ES,
Tyner AL, Gartel AL (2004) Constitutive expression of E2F-1 leads to
p21-dependent cell cycle arrest in S phase of the cell cycle. Oncogene 23:
4173–4176
Ribatti D, Gualandris A, Bastaki M, Vacca A, Iurlaro M, Roncali L, Presta M
(1997) New model for the study of angiogenesis and antiangiogenesis in
the chick embryo chorioallantoic membrane: the gelatin sponge/
chorioallantoic membrane assay. J Vasc Res 34: 455–463
Rubinfeld H, Seger R (2005) The ERK cascade: a prototype of MAPK
signaling. Mol Biotechnol 31: 151–174
Sa G, Stacey DW (2004) P27 expression is regulated by separate signaling
pathways, downstream of Ras, in each cell cycle phase. Exp Cell Res 300:
427–439
Schmidt U, Ahmed J, Michalsky E, Ho ¨pfner M, Preissner R (2008)
Comparative VEGF receptor tyrosine kinase modeling for the develop-
ment of highly specific inhibitors of tumor angiogenesis. Genome
Informatics. Int Conf Genome Informatics 20: 243–251
Schrader M, Kempkensteffen C, Christoph F, Hinz S, Weikert S, Lein M,
Krause H, Stefan C, Jung K, Ho ¨pfner M, Albers P, Miller K, Schostak M
(2009) Germ cell tumors of the gonads: a selective review emphasizing
problems in drug resistance and current therapy options. Oncology 76:
77–84
Shibuya M (2006) Vascular endothelial growth factor (VEGF)-Receptor2:
its biological functions, major signaling pathway, and specific ligand
VEGF-E. Endothelium J Endothelial Cell Res 13: 63–69
Takahashi K, Saishin Y, Saishin Y, Silva RL, Oshima Y, Oshima S, Melia M,
Paszkiet B, Zerby D, Kadan MJ, Liau G, Kaleko M, Connelly S, Luo T,
Campochiaro PA (2003) Intraocular expression of endostatin reduces
VEGF-induced retinal vascular permeability, neovascularization, and
retinal detachment. FASEB J Off Publ Federation Am Soc Exp Biol 17:
896–898
Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM (1996)
Significance of vessel count and vascular endothelial growth factor and
its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res Off J
Am Assoc Cancer Res 2: 1679–1684
Takano H, Murasawa S, Asahara T (2008) Functional and gene expression
analysis of hTERT overexpressed endothelial cells. Biologics Targets Ther
2: 547–554
Viglietto G, Romano A, Maglione D, Rambaldi M, Paoletti I, Lago CT,
Califano D, Monaco C, Mineo A, Santelli G, Manzo G, Botti G, Chiappetta
G, Persico MG (1996) Neovascularization in human germ cell tumors
correlates with a marked increase in the expression of the vascular
endothelial growth factor but not the placenta-derived growth factor.
Oncogene 13: 577–587
Voigt W, Kegel T, Maher G, Jordan K, Mu ¨ller L, Schmoll H (2006)
Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin
(HD-ICE) as third-line salvage chemotherapy induced an unexpected
dramatic response in highly platinum refractory germ-cell cancer.
Ann Oncol Off J Eur Soc Med Oncol/ESMO 17: 531–533
Wang N, Perkins KL, Bronson DL, Fraley EE (1981) Cytogenetic evidence
for premeiotic transformation of human testicular cancers. Cancer Res
41: 2135–2140
Wang Z, Kar S, Carr BI (2008) Cdc25A protein phosphatase: a therapeutic
target for liver cancer therapies. Anti-Cancer Agents Med Chem
(Formerly Curr Med Chem) 8: 863–871
Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F,
Mestan J, Mett H, O’Reilly T, Persohn E, Rosel J, Schnell C, Stover D,
Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister
G, Schirner M, Thierauch K, Schneider MR, Drevs J, Martiny-Baron G,
Totzke F, Marme D (2000) PTK787/ZK 222584, a novel and potent
inhibitor of vascular endothelial growth factor receptor tyrosine kinases,
impairs vascular endothelial growth factor-induced responses and tumor
growth after oral administration. Cancer Res 60: 2178–2189
Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, Que I,
Lowik C, Timpl R, Olsen BR (1999) Endostatin inhibits VEGF-induced
endothelial cell migration and tumor growth independently of zinc
binding. EMBO J 18: 4414–4423
Zhu H, Zhang L, Wu S, Teraishi F, Davis JJ, Jacob D, Fang B (2004)
Induction of S-phase arrest and p21 overexpression by a small molecule
2[[3-(2,3-dichlorophenoxy)propyl] amino]ethanol in correlation with
activation of ERK. Oncogene 23: 4984–4992
Molecular therapy of testicular germ cell tumours
B Nitzsche et al
28
British Journal of Cancer (2010) 103(1), 18–28 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s